Cascades (CAS) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
13 Nov, 2025Executive summary
Q3 2025 delivered strong operational execution, with Bear Island reaching 90% of ramp-up and 88% of rated capacity, and the Niagara Falls mill closure and tonnage redistribution completed ahead of schedule.
Sales reached $1,238 million, up 4% sequentially and 3% year-over-year, driven by higher selling prices, favorable FX, and improved volumes.
Profitability initiatives and operational improvements contributed to a 16% sequential and 14% year-over-year increase in consolidated EBITDA to $159 million.
Strategic focus remains on debt reduction, asset monetization, and operational excellence, with $57 million in asset sales including $31 million from Flexible Packaging.
Strategic initiatives generated approximately $10 million in sequential benefits, with ongoing cost reduction and productivity improvements.
Financial highlights
Adjusted EBITDA (A) was $159 million, up from $137 million in Q2 2025 and $140 million in Q3 2024; margin improved to 12.8%.
Net earnings were $29 million ($0.29 per share), compared to a loss of $3 million in Q2 2025 and $1 million in Q3 2024.
Adjusted net earnings were $39 million ($0.38 per share), up from $19 million ($0.19) in Q2 2025 and $27 million ($0.27) in Q3 2024.
Adjusted cash flow from operations was $137 million, up from $86 million a year ago and $101 million in Q2.
Net debt decreased by $81 million to $2,023 million; leverage ratio improved to 3.6x from 3.8x.
Outlook and guidance
Q4 2025 consolidated EBITDA (A) expected to range from -6% to +6% versus Q3, with packaging down 0–10% and tissue up 12–20%.
Packaging segment Q4 results expected to be stable to 10% below Q3, with a forecasted 5% volume decrease mainly in December.
Tissue segment results anticipated to strengthen sequentially due to lower raw material and maintenance costs.
Asset monetization target increased to $120 million by June 2026.
Profitability improvement initiatives on track for $100 million run rate by end of 2026.
Latest events from Cascades
- Margins, cash flow, and leverage improved in Q4, with asset sales and EBITDA (A) exceeding targets.CAS
Q4 202527 Feb 2026 - Q2 2024 saw sequential sales and EBITDA(A) growth, higher leverage, and a positive Q3 outlook.CAS
Q2 20242 Feb 2026 - Q3 margin and cash flow improved sequentially, but profit fell year-over-year on higher costs.CAS
Q3 202416 Jan 2026 - Q4 sales and EBITDA rose, but debt and tariff risks weigh on the outlook.CAS
Q4 202423 Dec 2025 - Q1 sales and EBITDA rose year-over-year, with Q2 growth expected despite ongoing trade risks.CAS
Q1 202526 Nov 2025 - Adjusted EBITDA (A) rose 22% year-over-year, but net loss was impacted by a $23M impairment charge.CAS
Q2 202523 Nov 2025 - US$400M note issuance to refinance debt and support growth amid strong market positioning.CAS
Investor Presentation1 Jul 2025 - 2024 sales reached $4.7B with EBITDA(A) of $501M, and margin recovery is expected in 2025.CAS
Investor Presentation1 Jul 2025 - Sustainability, innovation, and operational efficiency drive Cascades' growth and financial resilience.CAS
Investor Presentation13 Jun 2025